Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Utreloxastat (PTC857) is a novel 15-lipoxygenase inhibitor that can be used to study amyotrophic lateral sclerosis .
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 25,000 | |||
5 mg | 在庫あり | ¥ 62,500 | |||
10 mg | 在庫あり | ¥ 91,000 | |||
25 mg | 在庫あり | ¥ 152,000 | |||
50 mg | 在庫あり | ¥ 229,000 | |||
100 mg | 在庫あり | ¥ 397,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 57,000 |
説明 | Utreloxastat (PTC857) is a novel 15-lipoxygenase inhibitor that can be used to study amyotrophic lateral sclerosis . |
別名 | EPI 857, PTC857 |
分子量 | 276.41 |
分子式 | C18H28O2 |
CAS No. | 1213269-96-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (108.53 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Utreloxastat 1213269-96-5 Metabolism Lipoxygenase EPI 857 PTC857 Inhibitor inhibitor inhibit